Status:
COMPLETED
Ventricular Assist Device (VAD) Infection Prevention Survey
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Agency for Healthcare Research and Quality (AHRQ)
Conditions:
Heart Failure
Healthcare Associated Infection
Eligibility:
All Genders
18+ years
Brief Summary
Annually, more than 250,000 patients in the U.S. with end-stage heart failure stand to benefit from ventricular assist device (VAD) therapy. 60% of patients develop a healthcare-associated infection (...
Detailed Description
Annually, more than 250,000 patients in the U.S. with end-stage heart failure stand to benefit from ventricular assist device (VAD) therapy. Despite VADs providing long-term "durable" support, this th...
Eligibility Criteria
Inclusion
- Healthcare providers involved in the medical management of a Ventricular Assist Device (VAD) recipient during the peri-operative period, including those with the following roles: surgeons, cardiologists and VAD coordinators
Exclusion
- Healthcare providers not caring for VAD recipient patients.
Key Trial Info
Start Date :
May 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 23 2022
Estimated Enrollment :
208 Patients enrolled
Trial Details
Trial ID
NCT03843021
Start Date
May 29 2019
End Date
December 23 2022
Last Update
July 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109